ArticleInnere Medizin (Heidelberg, Germany)2026
[Prevention and prophylaxis in angiology].
Article in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular diseases develop over decades. Avoidable exposures, such as tobacco use and insufficient implementation of evidence-based prevention strategies contribute to the progression. For angiology, prevention and prophylaxis therefore means an integrated approach to structural prevention, primary prevention and secondary prevention. Structural prevention particularly addresses nicotine products, including e‑cigarettes/vapes and nutrition, such as reducing sugar in processed foods. Primary prevention includes risk-adapted early detection and risk reclassification, which do not rely on population-based screening but on clearly defined target groups with immediate therapeutic consequences. In the case of manifest atherosclerotic disease, secondary prevention aims to prevent subsequent events, such as progression of peripheral arterial occlusive disease (PAOD), myocardial infarction or stroke. Of particular relevance is the consistent implementation of supervised exercise training (SET) for intermittent claudication, as despite clear recommendations there is still a significant deficit in implementation on a broad scale. In Germany, the framework conditions for prevention and healthcare are basically in place (e.g., health check-ups, ultrasound screening for abdominal aortic aneurysm in men above the age of 65 years) but risk-adapted vascular risk stratification, reliable reimbursement and cross-sectoral programs such as SET/vascular exercise are not yet sufficiently systematized. This article identifies best practices, redundancies, evidence gaps and concrete areas for improvement and formulates practice-oriented and health policy-relevant lines of development.
Indexed as
Identifiers
41801342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.